# Controlled Values for PharmML Annotation Properties in DDMoRe

Implementation version: 1.3.0

- Pierre Grenon, University College London
- DDMoRe M66 August 2016

# <sub>6</sub> 1 Namespace used

- 7 pkpd http://www.ddmore.org/ontologies/ontology/pkpd-ontology
- 8 ncit http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
- 9 obo obo http://purl.obolibrary.org/obo/

# 2 Controlled Annotating Values

- wat:model-origin-of-code-in-literature-controlled
- 12 Yes
- 13 No
- wat:model-implementation-conforms-to-literature-controlled
- 15 Yes
- 16 No

#### 17 ps:model-modelling-question

- Patient Population Selection and Bridging between Population (Pediatrics, Elderly, Obese),
- 19 pkpd\_0006035
- Candidate Comparison, Selection, Human Dose Prediction, pkpd\_0006027
- <sup>21</sup> Mechanistic Understanding, pkpd\_0006026
- 22 Therapeutic Drug Monitoring, pkpd\_0006041
- Pharmaco-economic, pkpd\_0006038
- 24 Study Design Optimization, pkpd\_0006028

- 25 Pharmaco-epidemiologic, pkpd\_0006039
- Diagnostic model, pkpd\_0006042
- 27 Risk & Benefit Characterization, Outcome Prediction (Clinical & design Viability), pkpd\_0006032
- Disease Progression model, pkpd\_0006036
- 29 Combination Therapy Dose Selection, pkpd\_0006031
- 30 Similarity Assessment (MVC, Biosimilar, Formulation), pkpd\_0006030
- Dose & Schedule Selection and Label Recommendation, pkpd\_0006034
- Variability sources in PK and PD (CYP, Renal, Biomarkers), pkpd\_0006029
- 33 Social-economic, pkpd\_0006040
- Comparator/Standard of Care Differentiation (Clinical & Commercial Viability), pkpd\_0006033
- 35 Veterinary, pkpd\_0006043
- 36 Clinical end-point, pkpd\_0006037

#### ps:model-research-stage

- 1, Discovery stage, pkpd\_0006003
- 39 1.1, Fundamental/Basic research, pkpd\_0006004
- 40 1.2, Target selection & Validation, pkpd\_0006005
- 1.3, Lead Generation & Optimization, pkpd\_0006006
- 2, Preclinical development, pkpd\_0000050
- 43 2.1, In silico, pkpd\_0006007
- 44 2.2, In vitro, pkpd\_0000051
- 45 2.3, In vivo, pkpd\_0006008
- 46 3, Early clinical development (Phases I and II), pkpd\_0006009
- 4, Approval phase/Registration trial (Phase III), pkpd\_0006010
- 48 5, Life cycle management, pkpd\_0006011
- 6, Clinical research & Therapeutic use, pkpd\_0006012

#### 50 ps:model-field-purpose

- 51 Respiratory, pkpd\_0006018
- 52 CNS, pkpd\_0001023
- $_{53}$  Gastroenterology, pkpd\_0006021
- Metabolism, pkpd\_0006013
- 55 Cardiovascular, pkpd\_0006016
- 56 Immunology, pkpd\_0006023
- 57 Ophthalmology, pkpd\_0006015
- Vaccines, pkpd\_00060025
- 59 Endocrinology, pkpd\_0006020
- 60 Anti-infectives, pkpd\_0001024
- 61 Rheumatology, pkpd\_0006024

- 62 Diagnostics, pkpd\_0006019
- $_{63}$  Haematology, pkpd\_0006022
- $^{64}$  Oncology, pkpd\_0000036

#### ps:model-tasks-in-scope

- simulation, pkpd\_0006000
- estimation, pkpd\_0006001
- optimisation,  $pkpd_0006002$

# 69 ps:trialdesign-HasAssociatedDataOfType-DataPool

- 70 Published data, pkpd\_0000412
- Observations, pkpd\_0000411
- 72 Simulations, pkpd\_0000413

# ${\scriptstyle 73} \quad ps: model-Has Associated Data Of Type-Data Pool \\$

- 74 Published data, pkpd\_0000412
- Observations, pkpd\_0000411
- 76 Simulations, pkpd\_0000413

# 77 ps:trialdesign-HasAssociatedOrganismType-DataPool

- 78 dog, ncbit:9615
- 79 guinea pig, ncbit:10141
- monkey, ncbit:9527
- mouse, ncbit:10088
- 82 pig, ncbit:9823
- 83 rat, ncbit:10114
- rabbit, ncbit:9986

#### 85 ps:model-HasAssociatedOrganismType-DataPool

- 86 dog, ncbit:9615
- guinea pig, ncbit:10141
- 88 monkey, ncbit:9527
- mouse, ncbit:10088
- 90 pig, ncbit:9823
- 91 rat, ncbit:10114
- 92 rabbit, ncbit:9986

# 93 ps:trialdesign-HasAssociatedHumanGroupByMedicalStatus-DataPool

- 94 Healthy volunteer, pkpd\_0008012
- 95 Patient, pkpd\_0008011

# $_{96}$ ps:model-HasAssociatedHumanGroupByMedicalStatus-DataPool

- 97 Healthy volunteer, pkpd\_0008012
- 98 Patient, pkpd\_0008011

#### 99 ps:modellingstep-modelrun-uses-software

- 100 Berkeley-Madonna, pkpd\_0008000
- 101 Matlab, pkpd\_0000390
- Monolix, pkpd\_0000391
- 103 NONMEM, pkpd\_0000368
- 104 Openbugs, pkpd\_0008001
- 105 R, pkpd\_0001109
- 106 SAS, pkpd\_0008002
- 107 Winbugs, pkpd\_0008003

#### 108 ps:model-modelrun-uses-software

- Berkeley-Madonna, pkpd\_0008000
- 110 Matlab, pkpd\_0000390
- 111 Monolix, pkpd\_0000391
- 112 NONMEM, pkpd\_0000368
- 113 Openbugs, pkpd\_0008001
- 114 R, pkpd\_0001109
- 115 SAS, pkpd\_0008002
- 16 Winbugs, pkpd\_0008003

#### ps:trialdesign-HasAssociatedRouteOfAdministration-datapool

- 118 1, Parenteral, pkpd\_0008016
- 1.1, Intravenous, pkpd\_0008021
- 1.2, Subcutaneous, pkpd\_0008022
- 1.3, Intra-muscular, pkpd\_0008023
- 2, Enteral/Oral, pkpd\_0008017
- 123 3, Topical, pkpd\_0008018
- 3.1, Respiratory (i.e., inhalation), pkpd\_0008020
- 25 3.2, Transdermal, pkpd\_0008019

# $_{126}$ ps:model-HasAssociatedRouteOfAdministration-datapool

- 1, Parenteral, pkpd\_0008016
- 28 1.1, Intravenous, pkpd\_0008021
- 1.2, Subcutaneous, pkpd\_0008022
- 130 1.3, Intra-muscular, pkpd\_0008023
- 131 2, Enteral/Oral, pkpd\_0008017
- 3, Topical, pkpd\_0008018
- 3.1, Respiratory (i.e., inhalation), pkpd\_0008020
- 3.2, Transdermal, pkpd\_0008019

# ${\tt 135} \quad ps: trial design-Has Associated Dose Regimen-Data Pool$

- Single dose, pkpd\_0000423
- Multiple doses, pkpd\_0000424

# ps:model-HasAssociatedDoseRegimen-DataPool

- Single dose, pkpd\_0000423
- 140 Multiple doses, pkpd\_0000424

# ps:trialdesign-Has Associated Dose Amount-Data Pool

- 142 Fixed, pkpd\_0008025
- Flexible/adpted function of some criteria, pkpd\_0008026

#### ps:model-HasAssociatedDoseAmount-DataPool

- 145 Fixed, pkpd\_0008025
- Flexible/adpted function of some criteria, pkpd\_0008026

#### ps:trialdesign-HasAssociatedDoseFrequency-DataPool

- <sup>148</sup> QD (i.e. once per day), pkpd\_0008028
- BID (i.e. twice per day), pkpd\_0008029
- 150 TID (i.e. Three times a day), pkpd\_0008030
- QOD (i.e. every other day), pkpd\_0008031
- 152 Weekly, pkpd\_0008032
- QM (i.e. every month), pkpd\_0008033

#### $_{154}$ ps:model-HasAssociatedDoseFrequency-DataPool

- 155 QD (i.e. once per day), pkpd\_0008028
- BID (i.e. twice per day), pkpd\_0008029
- TID (i.e. Three times a day), pkpd\_0008030
- QOD (i.e. every other day), pkpd\_0008031
- 159 Weekly, pkpd\_0008032
- QM (i.e. every month), pkpd\_0008033

# $_{161}$ ps:trialdesign-observed-variables-are-real-freetext

- 162 Yes
- 163 No

#### ps:model-observed-variables-are-real-freetext

- 165 Yes
- 166 No

#### ps:trialdesign-HasAssociatedSamplingDesign-DataPool

- Assumed steady state, pkpd\_0008035
- Non steady state, pkpd\_0008037

#### ps:model-HasAssociatedSamplingDesign-DataPool

- Assumed steady state, pkpd\_0008035
- Non steady state, pkpd\_0008037

#### ps:modeldefinition-HasAssociatedInputType

- 174 1, Direct input (e.g., intravenous), pkpd\_0008050
- 1.1, Bolus, pkpd\_0000043
- 1.2, Infusion, pkpd\_0000044
- 2, Indirect input (e.g., oral), pkpd\_0008051
- 178 2.1, Absorption delay, pkpd\_0008052

#### ps:model-HasAssociatedInputType

- 180 1, Direct input (e.g., intravenous), pkpd\_0008050
- 181 1.1, Bolus, pkpd\_0000043
- 1.2, Infusion, pkpd\_0000044
- 2, Indirect input (e.g., oral), pkpd\_0008051

- 2.1, Absorption delay, pkpd\_0008052
- ${\tt ps:model definition-Has Associated Distribution Modelling Attribute}$
- -EnterohepaticRecycling
- 187 Yes, pkpd\_0008044
- 188 No, pkpd\_0008045
- ${\tt 189} \quad ps: model definition-Has Associated Distribution Modelling Attribute$
- 190 -NonLinearTransport
- 191 Yes, pkpd\_0008046
- <sup>192</sup> No, pkpd\_0008047
- ps:modeldefinition-HasAssociatedDistributionModellingAttribute
- -NonLinearProteinBinding
- 195 Yes, pkpd\_0008048
- 196 No, pkpd\_0008049
- ps:model-HasAssociatedDistributionModellingAttribute
- 198 -EnterohepaticRecycling
- 199 Yes, pkpd\_0008044
- 200 No, pkpd\_0008045
- 201 ps:model-HasAssociatedDistributionModellingAttribute
- 202 -NonLinearTransport
- <sup>203</sup> Yes, pkpd\_0008046
- No, pkpd\_0008047
- ps:model-HasAssociatedDistributionModellingAttribute
- 206 -NonLinearProteinBinding
- 207 Yes, pkpd\_0008048
- 208 No, pkpd\_0008049
- ps:modeldefinition-HasAssociatedAbsorptionDelayModelType
- 210 Lag time, pkpd\_0000075
- 211 Transit model, pkpd\_0008054

#### $_{212}$ ps:model-HasAssociatedAbsorptionDelayModelType

- 213 Lag time, pkpd\_0000075
- 214 Transit model, pkpd\_0008054

#### ps:modeldefinition-HasAssociatedAbsorptionRateType

- Zero order, pkpd\_0000071
- Sequential (e.g., zero order then first order), pkpd\_0008055
- 218 First order, pkpd\_0000072

#### 219 ps:model-HasAssociatedAbsorptionRateType

- Zero order, pkpd\_0000071
- Sequential (e.g., zero order then first order), pkpd\_0008055
- First order, pkpd\_0000072

# ps:model definition-Input Presents Formation From Other Substance-string

- 224 Yes
- 225 No

# ${\tt ps:model-InputPresentsFormationFromOtherSubstance-string}$

- 227 Yes
- 228 No

# ps:modeldefinition-HasAssociatedBioavailabilityType

- 230 1, Constant, pkpd\_0007016
- 231 2, Non constant, pkpd\_0007017
- 232 2.1, with dose, pkpd\_0007019
- 2.2, with concentration, pkpd\_0007021
- 2.3, with hepatic extraction (i.e., first-pass effect), pkpd\_0007022
- 2.4, with time, pkpd\_0007020

#### 236 ps:model-HasAssociatedBioavailabilityType

- 237 1, Constant, pkpd\_0007016
- 238 2, Non constant, pkpd\_0007017
- 239 2.1, with dose, pkpd\_0007019
- 2.2, with concentration, pkpd\_0007021
- 2.3, with hepatic extraction (i.e., first-pass effect), pkpd\_0007022

- 242 2.4, with time, pkpd\_0007020
- ps:modeldefinition-InputPresentsFormationFromOtherSubstanceType
- Administrated drug, pkpd\_0007028
- 245 Other, pkpd\_0007027
- ps:model-Input Presents Formation From Other Substance Type
- 247 Administrated drug, pkpd\_0007028
- 248 Other, pkpd\_0007027
- $_{249}$  ps:modeldefinition-InputPresentsFormationFromOtherSubstanceModelType
- 250 Linear, pkpd\_0007030
- Nonlinear, pkpd\_0007031
- Time-dependent, pkpd\_0007032
- ${\tt ps:model-InputPresentsFormationFromOtherSubstanceModelType}$
- <sup>254</sup> Linear, pkpd\_0007030
- Nonlinear, pkpd\_0007031
- Time-dependent,  $pkpd_0007032$
- ps:modeldefinition-HasAssociatedEliminationModellingAttribute
- -CompartmentOfElimination
- 259 Central, pkpd\_0007043
- Other than central, pkpd\_0007044
- ps:model-HasAssociatedEliminationModellingAttribute
- **-CompartmentOfElimination**
- <sup>263</sup> Central, pkpd\_0007043
- Other than central, pkpd\_0007044
- ps:modeldefinition-HasAssociatedEliminationModellingAttribute
- 266 -TypeOfElimination
- 1, Linear with drug concentration, pkpd\_0000054
- 268 2, Michaelis-Menten (MM), pkpd\_0000055
- 3, Target Mediated Drug Disposition (TMDD), pkpd\_0000500
- 4, Time dependent, pkpd\_0007046

- 271 4.1, Induction, pkpd\_0007047
- 272 4.2, Inhibition, pkpd\_0007048
- 273 4.3, Other, pkpd\_0008056

# 274 ps:model-HasAssociatedEliminationModellingAttribute

#### 275 -TypeOfElimination

- 276 1, Linear with drug concentration, pkpd\_0000054
- 277 2, Michaelis-Menten (MM), pkpd\_0000055
- 3, Target Mediated Drug Disposition (TMDD), pkpd\_0000500
- 4, Time dependent, pkpd\_0007046
- 280 4.1, Induction, pkpd\_0007047
- 281 4.2, Inhibition, pkpd\_0007048
- 282 4.3, Other, pkpd\_0008056

# ${\tt ps:model definition-Has Associated Modelled Drug Free System Type}$

- 284 1, Baseline, pkpd\_0008058
- 285 1.1, Constant, pkpd\_0008059
- 286 1.2, Non constant, pkpd\_0008060
- 287 2, Model for physiological system (description of some systems of physiology in healthy
- 288 state), pkpd\_0008061
- 3, Disease model (physiology system perturbed by the disease), pkpd\_0008062
- <sup>290</sup> 4, Other, pkpd\_0008063

# ${\tt ps:model-HasAssociatedModelledDrugFreeSystemType}$

- 292 1, Baseline, pkpd\_0008058
- $_{293}$  1.1, Constant, pkpd\_0008059
- 294 1.2, Non constant, pkpd\_0008060
- 295 2, Model for physiological system (description of some systems of physiology in healthy
- 296 state), pkpd\_0008061
- 3, Disease model (physiology system perturbed by the disease), pkpd\_0008062
- <sup>298</sup> 4, Other, pkpd\_0008063

# ${\tt ps:model definition-HasDriverOfDrugEffectTypeAttribute}$

- 300 1, Dose, pkpd\_0008065
- 2, Concentration profile, pkpd\_0008066
- 302 3, Summary measure, pkpd\_0008067
- 303 3.1, Average concentration, pkpd\_0008068
- 3.2, Minimal concentration or Through or pre-dose, pkpd\_0008069

- 3.3, Maximal concentration, pkpd\_0008070
- 3.4, AUC Over Dosing Interval, pkpd\_0008071
- 307 3.5, Time over a threshold concentration, pkpd\_0008072
- 308 3.6, Other, pkpd\_0008073

# $_{09}$ ps:model-HasDriverOfDrugEffectTypeAttribute

- 310 1, Dose, pkpd\_0008065
- 2, Concentration profile, pkpd\_0008066
- 3, Summary measure, pkpd\_0008067
- 3.1, Average concentration, pkpd\_0008068
- 3.2, Minimal concentration or Through or pre-dose, pkpd\_0008069
- 3.3, Maximal concentration, pkpd\_0008070
- 3.4, AUC Over Dosing Interval, pkpd\_0008071
- 3.5, Time over a threshold concentration, pkpd\_0008072
- 318 3.6, Other, pkpd\_0008073

# ${}_{\tt 319} \quad ps: model definition-HasShape Of Drug Effect Type Attribute$

- Linear relation, pkpd\_0008075
- 321 Emax/Imax, pkpd\_0008076
- 322 Sigmoid Emax/Imax, pkpd\_0008077
- 323 Other, pkpd\_0008078

#### ps:model-HasShapeOfDrugEffectTypeAttribute

- Linear relation, pkpd\_0008075
- 326 Emax/Imax, pkpd\_0008076
- 327 Sigmoid Emax/Imax, pkpd\_0008077
- 328 Other, pkpd\_0008078

# ps:modeldefinition-HasTemporalRelationBetweenDrugEffect

# $^{330}$ And Response Type Attribute

- 331 1, Direct, pkpd\_0008080
- 332 2, Indirect, pkpd\_0008081
- 2.1, Affecting production of response (kin), pkpd\_0008082
- 2.2, Affecting elimination of response (kout), pkpd\_0008083
- 335 3, Effect compartment, pkpd\_0008084
- 4, Binding model (i.e., to enzyme/receptor), pkpd\_0008085
- 5, Tolerance phenomena, pkpd\_0008086
- 338 6, Other, pkpd\_0008087

# ps:model-HasTemporalRelationBetweenDrugEffect AndResponseTypeAttribute

- 341 1, Direct, pkpd\_0008080
- <sup>342</sup> 2, Indirect, pkpd\_0008081
- 2.1, Affecting production of response (kin), pkpd\_0008082
- 2.2, Affecting elimination of response (kout), pkpd\_0008083
- 345 3, Effect compartment, pkpd\_0008084
- 4, Binding model (i.e., to enzyme/receptor), pkpd\_0008085
- 5, Tolerance phenomena, pkpd\_0008086
- 348 6, Other, pkpd\_0008087

#### $_{ ext{ iny 49}}$ ps:modeldefinition-HasModelForResponseType

- 350 1, Binary categorical observed variable, pkpd\_0007051
- 1.1, Logistic regression model, pkpd\_0007052
- 352 1.2, Markov model, pkpd\_0007053
- 2, Ordered categorical observed variable, pkpd\_0007054
- 2.1, Proportional odds model, pkpd\_0007055
- 2.2, Differential odds model, pkpd\_0007056
- 356 2.3, Markov model, pkpd\_0007057
- 357 3, Non-ordered categorical observed variable, pkpd\_0007058
- 358 3.1, Markov model, pkpd\_0007059
- 4, Count or frequency categorical observed variable, pkpd\_0007060
- 4.1, Poisson distribution model, pkpd\_0007061
- 4.2, Zero-inflated Poisson distribution model, pkpd\_0007062
- 4.3, Truncated poisson model, pkpd\_0007063
- 363 4.4, Generalized poisson model, pkpd\_0007064
- 4.5, Negative binomial model, pkpd\_0007065
- 4.6, Zero-inflated negative binomial model, pkpd\_0007066
- 366 4.7, Markov model, pkpd\_0007067
- 5, Time-to-event observed variable, pkpd\_0007068
- 5.1, Time-to-event single event observed variable, pkpd\_0007069
- 5.1.1, Semi-parametric survival model, pkpd\_0007070
- 370 5.1.1.1, Cox model, pkpd\_0007071
- 5.1.2, Parametric survival model, pkpd\_0007072
- 5.1.2.1, Exponential distribution model, pkpd\_0007073
- 5.1.2.2, Weibull distribution model, pkpd\_0007074
- 5.1.2.3, Log-normal distribution model, pkpd\_0007075
- 5.1.2.4, Gamma distribution model, pkpd\_0007076
- 376 5.1.2.5, Gompertz model, pkpd\_0007077

- 5.2, Time-to-event repeated event observed variable, pkpd\_0007078
- 378 5.2.1, Markov model, pkpd\_0007079

#### ps:model-HasModelForResponseType

- 1, Binary categorical observed variable, pkpd\_0007051
- 381 1.1, Logistic regression model, pkpd\_0007052
- 382 1.2, Markov model, pkpd\_0007053
- 2, Ordered categorical observed variable, pkpd\_0007054
- 2.1, Proportional odds model, pkpd\_0007055
- 2.2, Differential odds model, pkpd\_0007056
- 386 2.3, Markov model, pkpd\_0007057
- 387 3, Non-ordered categorical observed variable, pkpd\_0007058
- 3.1, Markov model, pkpd\_0007059
- 4, Count or frequency categorical observed variable, pkpd\_0007060
- 390 4.1, Poisson distribution model, pkpd\_0007061
- 4.2, Zero-inflated Poisson distribution model, pkpd\_0007062
- 392 4.3, Truncated poisson model, pkpd\_0007063
- 393 4.4, Generalized poisson model, pkpd\_0007064
- 4.5, Negative binomial model, pkpd\_0007065
- 4.6, Zero-inflated negative binomial model, pkpd\_0007066
- 396 4.7, Markov model, pkpd\_0007067
- 5, Time-to-event observed variable, pkpd\_0007068
- 5.1, Time-to-event single event observed variable, pkpd\_0007069
- 5.1.1, Semi-parametric survival model, pkpd\_0007070
- 400 5.1.1.1, Cox model, pkpd\_0007071
- 401 5.1.2, Parametric survival model, pkpd\_0007072
- 5.1.2.1, Exponential distribution model, pkpd\_0007073
- 5.1.2.2, Weibull distribution model, pkpd\_0007074
- 404 5.1.2.3, Log-normal distribution model, pkpd\_0007075
- 5.1.2.4, Gamma distribution model, pkpd\_0007076
- 406 5.1.2.5, Gompertz model, pkpd\_0007077
- 5.2, Time-to-event repeated event observed variable, pkpd\_0007078
- 408 5.2.1, Markov model, pkpd\_0007079

#### ps:trialdesign-HasStudiedSubstanceAtttibute

- 410 Drug/Investigational agent/Hypothetical drug, C1909
- 411 No drug, C14165
- Placebo, C753
- Stimulus (ex: glucose tolerance test), C41210

#### $_{ m 414}$ ps:model-HasStudiedSubstanceAtttibute

- <sup>415</sup> Drug/Investigational agent/Hypothetical drug, C1909
- No drug, C14165
- <sup>417</sup> Placebo, C753
- Stimulus (ex: glucose tolerance test), C41210

# ps:drug-TypeOfDrug1

- 420 Antibody orother biological drug, pkpd\_0007173
- Small molecule, pkpd\_0007174

# ps:drug-TypeOfDrug2

- 423 Antibody orother biological drug, pkpd\_0007173
- 424 Small molecule, pkpd\_0007174

# ps:drug-TypeOfDrug3

- 426 Antibody orother biological drug, pkpd\_0007173
- 427 Small molecule, pkpd\_0007174

# $_{428}$ ps:drug-TypeOfDrug4

- 429 Antibody orother biological drug, pkpd\_0007173
- Small molecule, pkpd\_0007174

#### ps:drug-TypeOfDrug5

- 432 Antibody orother biological drug, pkpd\_0007173
- Small molecule, pkpd\_0007174

#### ps:trialdesign-hasInteractorByNickname-freetext

- 435 Drug1
- 436 Drug2
- 437 Drug3
- 438 Drug4
- 439 Drug5
- 440 OV1
- 441 OV2
- 442 OV3
- 443 OV4

444 OV5

#### $_{ ext{ iny 145}}$ ps:trialdesign-hasInteracteeByNickname-freetext

- 446 Drug1
- 447 Drug2
- 448 Drug3
- 449 Drug4
- 450 Drug5
- 451 OV1
- 452 OV2
- 453 OV3
- 454 OV4
- 455 OV5

#### ps:trialdesign-hasTypeOfModelComponentImpacted

- 1, PK, pkpd\_000006
- 458 1.1, Drug metabolism or transport, pkpd\_0008101
- 1.1.1, Inhibition reversible or irreversible, pkpd\_0008102
- 460 1.1.2, Induction of enzymes or transporters, pkpd\_0008103
- 1.2, Binding to plasma protein(s), pkpd\_0008104
- 462 2, PD, pkpd\_0000007

#### ps:model-hasTypeOfModelComponentImpacted

- 464 1, PK, pkpd\_0000006
- 465 1.1, Drug metabolism or transport, pkpd\_0008101
- 1.1.1, Inhibition reversible or irreversible, pkpd\_0008102
- 467 1.1.2, Induction of enzymes or transporters, pkpd\_0008103
- 1.2, Binding to plasma protein(s), pkpd\_0008104
- 469 2, PD, pkpd\_000007

# ${\bf ps:} {\bf model-hasInteractorByNickname-free text}$

- 471 Drug1
- 472 Drug2
- 473 Drug3
- 474 Drug4
- 475 Drug5
- 476 OV1
- 477 OV2

```
OV3
   OV4
   OV5
   ps:model-hasInteracteeByNickname-freetext
481
   Drug1
   Drug2
483
   Drug3
484
   Drug4
485
   Drug5
486
   OV1
487
   OV2
488
   OV3
   OV4
490
   OV5
491
   ps: drug-has Dose Amount Unit-Drug 1\\
   mg, C28253
493
   ug, C48152
494
   IU (international unit), C48579
495
   ml, C28254
496
   ps:drug-hasDoseAmountUnit-Drug2
   mg, C28253
498
   ug, C48152
499
   IU (international unit), C48579
   ml, C28254
501
   ps:drug-hasDoseAmountUnit-Drug3
   mg, C28253
503
   ug, C48152
   IU (international unit), C48579
   ml, C28254
   ps: drug-has Dose Amount Unit-Drug 4\\
   mg, C28253
   ug, C48152
```

```
IU (international unit), C48579
   ml, C28254
   ps:drug-hasDoseAmountUnit-Drug5
512
   mg, C28253
   ug, C48152
   IU (international unit), C48579
   ml, C28254
   ps:model-hasDoseAmountUnit-Drug1
   mg, C28253
518
   ug, C48152
519
   IU (international unit), C48579
   ml, C28254
521
   ps:model-hasDoseAmountUnit-Drug2
522
   mg, C28253
523
   ug, C48152
524
   IU (international unit), C48579
   ml, C28254
   ps:model-hasDoseAmountUnit-Drug3
   mg, C28253
528
   ug, C48152
   IU (international unit), C48579
   ml, C28254
531
   ps:model-hasDoseAmountUnit-Drug4
   mg, C28253
533
   ug, C48152
   IU (international unit), C48579
   ml, C28254
```

#### ps:model-hasDoseAmountUnit-Drug5

- <sub>538</sub> mg, C28253
- <sup>539</sup> ug, C48152
- 540 IU (international unit), C48579
- 541 ml, C28254

# ps:model-OVLinksToDrug-OV1

- 543 Drug1
- 544 Drug2
- 545 Drug3
- 546 Drug4
- 547 Drug5

# ps:model-OVHasNature-OV1

- Concentration, PATO\_0000033
- 550 Score, C25338

# ps:model-OVHasMatrixType-OV1

- 552 Blood, FMA\_9670
- <sup>553</sup> Cerebrospinal Fluid (CSF), FMA\_20935
- 554 Plasma, FMA\_62970
- 555 Serum, FMA\_63083
- 556 Urine, FMA\_12274

#### ps:model-OVHasTypeOfObservedVariable-OV1

- 558 1, Continuous, pkpd\_0000415
- 559 2, Categorical, pkpd\_0000416
- 3, Count, pkpd\_000418
- <sup>561</sup> 4, Frequency, pkpd\_0008105
- 562 5, Time-to-event, pkpd\_0000417

#### ps:model-OVLinksToDrug-OV2

- 564 Drug1
- 565 Drug2
- 566 Drug3
- 567 Drug4
- 568 Drug5

# ps:model-OVHasNature-OV2

- 570 Concentration, PATO\_0000033
- 571 Score, C25338

#### ps:model-OVHasMatrixType-OV2

- 573 Blood, FMA\_9670
- <sup>574</sup> Cerebrospinal Fluid (CSF), FMA\_20935
- 575 Plasma, FMA\_62970
- 576 Serum, FMA\_63083
- 577 Urine, FMA\_12274

# ps:model-OVHasTypeOfObservedVariable-OV2

- 579 1, Continuous, pkpd\_0000415
- $_{580}$  2, Categorical, pkpd\_0000416
- <sup>581</sup> 3, Count, pkpd\_0000418
- <sup>582</sup> 4, Frequency, pkpd\_0008105
- 583 5, Time-to-event, pkpd\_0000417

# ps:model-OVLinksToDrug-OV3

- 585 Drug1
- 586 Drug2
- 587 Drug3
- 588 Drug4
- 589 Drug5

#### ps:model-OVHasNature-OV3

- Concentration, PATO\_0000033
- 592 Score, C25338

#### ps:model-OVHasMatrixType-OV3

- 594 Blood, FMA\_9670
- <sup>595</sup> Cerebrospinal Fluid (CSF), FMA\_20935
- 596 Plasma, FMA\_62970
- 597 Serum, FMA\_63083
- 598 Urine, FMA\_12274

# ps:model-OVHasTypeOfObservedVariable-OV3

- 600 1, Continuous, pkpd\_0000415
- 2, Categorical, pkpd\_0000416
- 602 3, Count, pkpd\_0000418
- 603 4, Frequency, pkpd\_0008105
- 5, Time-to-event, pkpd\_0000417

#### ps:model-OVLinksToDrug-OV4

- 606 Drug1
- 607 Drug2
- 608 Drug3
- 609 Drug4
- 610 Drug5

# ps:model-OVHasNature-OV4

- 612 Concentration, PATO\_0000033
- 613 Score, C25338

# ps:model-OVHasMatrixType-OV4

- 615 Blood, FMA\_9670
- 616 Cerebrospinal Fluid (CSF), FMA\_20935
- 617 Plasma, FMA\_62970
- 618 Serum, FMA\_63083
- 619 Urine, FMA\_12274

#### $_{620}$ ps:model-OVHasTypeOfObservedVariable-OV4

- 1, Continuous, pkpd\_0000415
- 2, Categorical, pkpd\_0000416
- 623 3, Count, pkpd\_0000418
- 4, Frequency, pkpd\_0008105
- 5, Time-to-event, pkpd\_0000417

# $_{626}$ ps:model-OVLinksToDrug-OV5

- 627 Drug1
- 628 Drug2
- 629 Drug3
- 630 Drug4

#### 631 Drug5

#### ps:model-OVHasNature-OV5

- 633 Concentration, PATO\_0000033
- 634 Score, C25338

#### ps:model-OVHasMatrixType-OV5

- 636 Blood, FMA\_9670
- 637 Cerebrospinal Fluid (CSF), FMA\_20935
- 638 Plasma, FMA\_62970
- 639 Serum, FMA\_63083
- 640 Urine, FMA\_12274

#### ps:model-OVHasTypeOfObservedVariable-OV5

- 1, Continuous, pkpd\_0000415
- 2, Categorical, pkpd\_0000416
- 3, Count, pkpd\_0000418
- 4, Frequency, pkpd\_0008105
- 5, Time-to-event, pkpd\_0000417

# $_{647}$ ps:structuralmodel-HasComponentType

- 648 PK, pkpd\_000006
- PD, pkpd\_0000007
- 650 PBPK, pkpd\_0000012
- Drug-Drug Interaction, pkpd\_0008100

#### ps:model-HasComponentType

- 953 PK, pkpd\_000006
- PD, pkpd\_0000007
- 655 PBPK, pkpd\_0000012
- Drug-Drug Interaction, pkpd\_0008100

- 658 1, concentration, C48207
- 659 1.1, nM, C48517
- 660 1.2, uM, C48509
- 661 1.3, ng/mL, C67306

- 562 1.4, mg/mL, C42576
- $1.5, \, \mathrm{mg/dL}, \, \mathrm{C67015}$
- 664 1.6, ug/mL, C67305
- 665 1.7, g/L, C42576
- 666 1.8, mg/L, C67306
- 667 1.9, number/L, C105515
- <sup>668</sup> "1.10", number/mL, C103452
- 669 1.11, IU/mL, C67377
- 670 1.12, IU/L, C67376
- 1.13, mIU/L, C67405
- 672 2, volume, C44279
- 673 2.1, L, C48505
- 674 2.2, mL, C28254
- 675 2.3, mm3, C48153
- 676 2.4, cm3, C28254
- 677 3, length, C42578
- 678 3.1, mm, C28251
- 679 3.2, cm, C49668
- 680 3.2, m, C41139
- 681 4, area, C48037
- 682 4.1, mm2, C65104
- 683 4.2, cm2, C48460
- 684 5, clearance, C48568
- 685 5.1, L/h, C69160
- 686 5.2, L/min, C67388
- 5.3, mL/h, C66962
- 688 6, rate, C25636
- 689 6.1, h-1, C66966
- 690 6.2, min-1, C66967
- 691 6.3, day-1, C66968
- 692 6.4, week-1, C67069
- 693 6.5, year-1, C74924
- 694 7, time, C42574
- 695 7.1, h, C25529
- 696 7.2, min, C48154
- 697 7.3, day, C25301
- 698 7.4, week, C29844
- 699 7.5, year, C29848
- 700 8, amount, C42579
- 701 8.1, g, C48155
- 702 8.2, mg, C28253

- 8.3, kg, C28252
- 8.4, International Unit (IU), C48579

# ps: model-OVH as Units-OV2

- 1, concentration, C48207
- 1.1, nM, C48517 707
- 1.2, uM, C48509 708
- 1.3, ng/mL, C67306 709
- 1.4, mg/mL, C42576 710
- 1.5, mg/dL, C67015 711
- 1.6, ug/mL, C67305 712
- 1.7, g/L, C42576
- 1.8, mg/L, C67306
- 1.9, number/L, C105515
- "1.10", number/mL, C103452
- 1.11, IU/mL, C67377 717
- 1.12, IU/L, C67376 718
- 1.13, mIU/L, C67405 719
- 2, volume, C44279 720
- 2.1, L, C48505
- 2.2, mL, C28254
- 2.3, mm3, C48153
- 2.4, cm3, C28254 724
- 3, length, C42578 725
- 3.1, mm, C28251 726
- 3.2, cm, C49668 727
- 3.2, m, C41139
- 728
- 4, area, C48037 729 4.1, mm2, C65104 730
- 4.2, cm2, C48460 731
- 5, clearance, C48568 732
- 5.1, L/h, C69160 733
- 5.2, L/min, C67388 734
- 5.3, mL/h, C66962 735
- 6, rate, C25636
- 6.1, h-1, C66966
- 6.2, min-1, C66967 738
- 6.3, day-1, C66968 739
- 6.4, week-1, C67069
- 6.5, year-1, C74924

- 7, time, C42574
- 7.1, h, C25529
- 7.2, min, C48154 744
- 7.3, day, C25301 745
- 7.4, week, C29844 746
- 7.5, year, C29848 747
- 8, amount, C42579 748
- 8.1, g, C48155
- 8.2, mg, C28253
- 8.3, kg, C28252 751
- 8.4, International Unit (IU), C48579 752

- 1, concentration, C48207 754
- 1.1, nM, C48517 755
- 1.2, uM, C48509 756
- 1.3, ng/mL, C67306 757
- 1.4, mg/mL, C42576 758
- 1.5, mg/dL, C67015 759
- 1.6, ug/mL, C67305
- 1.7, g/L, C42576
- 1.8, mg/L, C67306 762
- 1.9, number/L, C105515 763
- "1.10", number/mL, C103452 764
- 1.11, IU/mL, C67377 765
- 1.12, IU/L, C67376 766
- 1.13, mIU/L, C67405
- 2, volume, C44279
- 2.1, L, C48505
- 2.2, mL, C28254 770
- 2.3, mm3, C48153 771
- 2.4, cm3, C28254 772
- 3, length, C42578 773
- 3.1, mm, C28251 774
- 3.2, cm, C49668 775
- 3.2, m, C41139
- 4, area, C48037
- 777
- 4.1, mm2, C65104
- 4.2, cm2, C48460
- 5, clearance, C48568

- 781 5.1, L/h, C69160
- <sub>82</sub> 5.2, L/min, C67388
- <sub>783</sub> 5.3, mL/h, C66962
- 784 6, rate, C25636
- 785 6.1, h-1, C66966
- 786 6.2, min-1, C66967
- 787 6.3, day-1, C66968
- 788 6.4, week-1, C67069
- 789 6.5, year-1, C74924
- 790 7, time, C42574
- 791 7.1, h, C25529
- 792 7.2, min, C48154
- 793 7.3, day, C25301
- 794 7.4, week, C29844
- 795 7.5, year, C29848
- 796 8, amount, C42579
- 797 8.1, g, C48155
- 798 8.2, mg, C28253
- 799 8.3, kg, C28252
- 800 8.4, International Unit (IU), C48579

- 802 1, concentration, C48207
- 803 1.1, nM, C48517
- 804 1.2, uM, C48509
- 805 1.3, ng/mL, C67306
- 806 1.4, mg/mL, C42576
- 807 1.5, mg/dL, C67015
- os 1.6, ug/mL, C67305
- 809 1.7, g/L, C42576
- 810 1.8, mg/L, C67306
- 811 1.9, number/L, C105515
- \*\*1.10", number/mL, C103452
- 813 1.11, IU/mL, C67377
- 1.12, IU/L, C67376
- 815 1.13, mIU/L, C67405
- 816 2, volume, C44279
- 817 2.1, L, C48505
- 818 2.2, mL, C28254
- 819 2.3, mm3, C48153

- 2.4, cm<sup>3</sup>, C<sup>28254</sup>
- 3, length, C42578
- 822 3.1, mm, C28251
- 823 3.2, cm, C49668
- 824 3.2, m, C41139
- 825 4, area, C48037
- 826 4.1, mm2, C65104
- 4.2, cm2, C48460
- 828 5, clearance, C48568
- 829 5.1, L/h, C69160
- 830 5.2, L/min, C67388
- 831 5.3, mL/h, C66962
- 832 6, rate, C25636
- 833 6.1, h-1, C66966
- 834 6.2, min-1, C66967
- 835 6.3, day-1, C66968
- 836 6.4, week-1, C67069
- 837 6.5, year-1, C74924
- 838 7, time, C42574
- 839 7.1, h, C25529
- 840 7.2, min, C48154
- 841 7.3, day, C25301
- 842 7.4, week, C29844
- 843 7.5, year, C29848
- 8, amount, C42579
- 845 8.1, g, C48155
- 846 8.2, mg, C28253
- 847 8.3, kg, C28252
- 848 8.4, International Unit (IU), C48579

- 850 1, concentration, C48207
- 851 1.1, nM, C48517
- 852 1.2, uM, C48509
- 853 1.3, ng/mL, C67306
- 854 1.4, mg/mL, C42576
- 855 1.5, mg/dL, C67015
- 856 1.6, ug/mL, C67305
- 857 1.7, g/L, C42576
- 858 1.8, mg/L, C67306

- 859 1.9, number/L, C105515
- 360 "1.10", number/mL, C103452
- 861 1.11, IU/mL, C67377
- 862 1.12, IU/L, C67376
- 863 1.13, mIU/L, C67405
- 864 2, volume, C44279
- 865 2.1, L, C48505
- 866 2.2, mL, C28254
- 867 2.3, mm3, C48153
- 868 2.4, cm3, C28254
- 3, length, C42578
- 870 3.1, mm, C28251
- 3.2, cm, C49668
- 872 3.2, m, C41139
- 873 4, area, C48037
- 874 4.1, mm2, C65104
- 875 4.2, cm2, C48460
- 876 5, clearance, C48568
- 877 5.1, L/h, C69160
- 878 5.2, L/min, C67388
- 879 5.3, mL/h, C66962
- 880 6, rate, C25636
- 881 6.1, h-1, C66966
- 882 6.2, min-1, C66967
- 6.3, day-1, C66968
- 884 6.4, week-1, C67069
- 885 6.5, year-1, C74924
- 886 7, time, C42574
- 887 7.1, h, C25529
- 888 7.2, min, C48154
- 889 7.3, day, C25301
- <sup>890</sup> 7.4, week, C29844
- 891 7.5, year, C29848
- 892 8, amount, C42579
- 893 8.1, g, C48155
- 894 8.2, mg, C28253
- 895 8.3, kg, C28252
- 896 8.4, International Unit (IU), C48579